Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269470 | 0.81 | HCAR2 (0.32) | RAB9AMAPTALDH1A1CA1GAA | |
| SCHEMBL13360253 | 0.72 | LMNA (0.35) | NPC1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL10127313 | 0.71 | NPC1 (0.44) | NPC1RAB9ALMNAKDM4AMAPT | |
| SCHEMBL18884210 | 0.67 | KDM4E (0.50) | MAPTALDH1A1GAA | |
| SCHEMBL13462532 | 0.56 | PDE3B (0.36) | ALDH1A1HPGDGAA | |
| SCHEMBL30107638 | 0.55 | — | — | |
| SCHEMBL9062085 | 0.55 | IDH1 (0.44) | RAB9ALMNAMAPTALDH1A1HPGD | |
| SCHEMBL8408224 | 0.55 | RPS6KA3 (0.69) | NPC1RAB9ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL9052845 | 0.55 | POLB (0.35) | MAPTALDH1A1GAA | |
| SCHEMBL10197127 | 0.55 | SMPD3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | Orphagen Pharmaceuticals, Inc. | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357175-A1 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | RARA, RARB, RARG | NPC1 1909/4885RAB9A 1704/4885LMNA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.